Via National Keratoconus Foundation Corneal collagen cross-linking (CXL) has been shown to be an efficient treatment option to slow or halt the progression of keratoconus. As the US keratoconus community waits patiently (?) for FDA approval of basic corneal crosslinking, researchers in other countries are exploring advanced variations to improve this procedure. In biological and … Continue reading Three Different Protocols for CXL
Month: December 2015
Looking Ahead To 2017
Happy New Year to the #kcfamily